Ruxotor 10 mg (Ruxolitinib Phosphate)
Ruxotor 10 mg (Ruxolitinib Phosphate) is an oral prescription medicine used primarily to treat certain blood and bone marrow disorders. It contains Ruxolitinib Phosphate, a targeted therapy that works by inhibiting specific enzymes involved in the growth and survival of abnormal blood cells. Ruxotor 10 mg belongs to a class of medicines known as Janus kinase (JAK) inhibitors, which help regulate overactive signaling pathways in the body.
What Is Ruxotor 10 mg Used For?
Ruxotor 10 mg is commonly prescribed for conditions such as:
Myelofibrosis (MF) – including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis
Polycythemia Vera (PV) in patients who have had an inadequate response or intolerance to hydroxyurea
Graft-versus-host disease (GVHD) in certain cases after stem cell transplantation
Myelofibrosis and polycythemia vera are types of myeloproliferative neoplasms (MPNs), which are disorders where the bone marrow produces too many abnormal blood cells. These conditions can cause symptoms such as enlarged spleen, fatigue, night sweats, itching, bone pain, and weight loss. Ruxotor helps control these symptoms and may reduce spleen size.
How Does Ruxolitinib Phosphate Work?
Ruxolitinib selectively inhibits JAK1 and JAK2 enzymes. These enzymes are part of the JAK-STAT signaling pathway, which plays a key role in blood cell production and immune system function. In conditions like myelofibrosis and polycythemia vera, this pathway becomes overactive due to genetic mutations such as JAK2 V617F.
By blocking JAK1 and JAK2, Ruxotor reduces abnormal cell signaling, helping to:
Decrease excessive blood cell production
Reduce inflammation
Improve constitutional symptoms
Shrink an enlarged spleen
This targeted mechanism allows for better disease control compared to traditional chemotherapy.
Dosage and Administration
Ruxotor 10 mg tablets are taken orally, usually twice daily, with or without food. The exact dose depends on the patient’s condition, platelet count, and overall health status. Doctors may adjust the dosage based on treatment response and blood test results.
Patients are advised to take the medicine at the same times each day to maintain consistent drug levels in the body. It is important not to stop or change the dose without consulting a healthcare professional, as sudden discontinuation may worsen symptoms.
Possible Side Effects
Like all medications, Ruxotor 10 mg may cause side effects. Common side effects include:
Anemia (low red blood cell count)
Thrombocytopenia (low platelet count)
Neutropenia (low white blood cell count)
Dizziness
Headache
Bruising
Increased risk of infections
Because Ruxolitinib affects the immune system, patients may be more susceptible to infections, including viral, bacterial, or fungal infections. Regular blood tests are required to monitor blood counts and ensure safe treatment.
Serious but less common side effects may include severe infections, reactivation of tuberculosis, or certain skin cancers. Immediate medical attention is required if unusual symptoms occur.
Warnings and Precautions
Before starting Ruxotor 10 mg, patients should inform their doctor about:
Any history of infections
Liver or kidney problems
Tuberculosis exposure
Other medications being taken
Pregnancy or breastfeeding status
Ruxolitinib may interact with certain medications, particularly strong CYP3A4 inhibitors or inducers. Careful dose adjustment may be necessary.
Storage and Handling
Store Ruxotor 10 mg tablets at room temperature, away from moisture and direct sunlight. Keep the medication out of reach of children. Do not use after the expiry date printed on the packaging.
Conclusion
Ruxotor 10 mg (Ruxolitinib Phosphate) is an effective targeted therapy for treating myelofibrosis, polycythemia vera, and certain cases of graft-versus-host disease. By inhibiting the JAK signaling pathway, it helps reduce symptoms, control abnormal blood cell production, and improve quality of life. As with any prescription medicine, it should be used under medical supervision with regular monitoring to ensure safety and effectiveness.